1. Wick JY. The history of benzodiazepines. Consult Pharm. 2013 Sep;28(9):538-48. doi: 10.4140/TCP.n.2013.538. PMID: 24007886.

2 Demyttenaere K, Bonnewyn A, Bruffaerts R, De Girolamo G, Gasquet I, Kovess V, Haro JM, Alonso J. Clinical factors influencing the prescription of antidepressants and benzodiazepines: results from the European study of the epidemiology of mental disorders (ESEMeD). J Affect Disord. 2008 Sep;110(1-2):84-93. doi: 10.1016/j.jad.2008.01.011. Epub 2008 Mar 10. PMID: 18329721.

3. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015 Feb;72(2):136-42. doi: 10.1001/jamapsychiatry.2014.1763. PMID: 25517224.

4. Maust DT, Lin LA, Blow FC. Benzodiazepine Use and Misuse Among Adults in the United States. Psychiatr Serv. 2019 Feb 1;70(2):97-106. doi: 10.1176/appi.ps.201800321. Epub 2018 Dec 17. PMID: 30554562; PMCID: PMC6358464.

5. Hirschtritt ME, Olfson M, Kroenke K. Balancing the Risks and Benefits of Benzodiazepines. JAMA. 2021 Jan 26;325(4):347-348. doi: 10.1001/jama.2020.22106. PMID: 33416846.

6. Stahl SM. Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (4^th ed.). Cambridge University Press. 2013.

7. Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, Lidbetter N, Malizia A, McCrone P, Nabarro D, O’Neill C, Scott J, van der Wee N, Wittchen HU. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessivecompulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014 May;28(5):403-39. doi: 10.1177/0269881114525674. Epub 2014 Apr 8. PMID: 24713617.

8. Perna G, Alciati A, Riva A, Micieli W, Caldirola D. Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. Curr Psychiatry Rep. 2016 Mar;18(3):23. doi: 10.1007/s11920-016-0668-3. PMID: 26830881.

9. Chouinard G, Annable L, Fontaine R, Solyom L. Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study. Psychopharmacology (Berl). 1982;77(3):229-33. doi: 10.1007/BF00464571. PMID: 6126907.

10. Elie R, Lamontagne Y. Alprazolam and diazepam in the treatment of generalized anxiety. J Clin Psychopharmacol. 1984 Jun;4(3):125-9. PMID: 6145726.

11. Fontaine R, Mercier P, Beaudry P, Annable L, Chouinard G. Bromazepam and lorazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. Acta Psychiatr Scand. 1986 Nov;74(5):451-8. doi: 10.1111/j.1600-0447.1986.tb06268.x. PMID: 2880459.

12. Spénard J, Caillé G, de Montigny C, Vézina M, Ouellette J, Larivière L, Trudel F. Placebo-controlled comparative study of the anxiolytic activity and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety. Biopharm Drug Dispos. 1988 Sep-Oct;9(5):457-64. doi: 10.1002/ bod.2510090504. PMID: 3066417.

13. Kragh-Sørensen P, Holm P, Fynboe C, Schaumburg E, Andersen B, Bech P, Pichard J. Bromazepam in generalized anxiety. Randomized, multi-practice comparisons with both chlorprothixene and placebo. Psychopharmacology (Berl). 1990;100(3):383-6. doi: 10.1007/BF02244611. PMID: 1969172.

14. Hackett D, Haudiquet V, Salinas E. A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. Eur Psychiatry. 2003 Jun;18(4):182-7. doi: 10.1016/s0924-9338(03)00046-4. PMID: 12814852.

15. Feltner DE, Harness J, Brock J, Sambunaris A, Cappelleri JC, Morlock R. Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder. CNS Neurosci Ther. 2009 Winter;15(1):12-8. doi: 10.1111/j.1755-5949.2008.00075.x. PMID: 19228175; PMCID: PMC6494008.

16. Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. Expert Opin Pharmacother. 2018 Jun;19(8):883-894. doi: 10.1080/14656566.2018.1472767. Epub 2018 May 28. PMID: 29806492; PMCID: PMC6097846.

17. Reinhold JA, Rickels K. Pharmacological treatment for generalized anxiety disorder in adults: an update. Expert Opin Pharmacother. 2015;16(11):1669-81. doi: 10.1517/14656566.2015.1059424. PMID: 26159446.

18. Ballenger JC, Burrows GD, DuPont RL Jr, Lesser IM, Noyes R Jr, Pecknold JC, Rifkin A, Swinson RP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry. 1988 May;45(5):413-22. doi: 10.1001/ archpsyc.1988.01800290027004. PMID: 3282478.

19. Noyes R Jr, DuPont RL Jr, Pecknold JC, Rifkin A, Rubin RT, Swinson RP, Ballenger JC, Burrows GD. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. Arch Gen Psychiatry. 1988 May;45(5):423-8. doi: 10.1001/ archpsyc.1988.01800290037005. PMID: 3358644.

20. Schweizer E, Pohl R, Balon R, Fox I, Rickels K, Yeragani VK. Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry. 1990 Mar;23(2):90-3. doi: 10.1055/s-2007-1014489. PMID: 2187213.

21. Charney DS, Woods SW. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry. 1989 Nov;50(11):418-23. PMID: 2808308.

22. Offidani E, Guidi J, Tomba E, Fava GA. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom. 2013;82(6):355-62. doi: 10.1159/000353198. Epub 2013 Sep 20. PMID: 24061211.

23. Nardi AE, Valença AM, Freire RC, Mochcovitch MD, Amrein R, Sardinha A, Levitan MN, Nascimento I, de-Melo-Neto VL, King AL, de O E Silva AC, Veras AB, Dias GP, Soares-Filho GL, da Costa RT, Mezzasalma MA, de Carvalho MR, de Cerqueira AC, Hallak JE, Crippa JA, Versiani M. Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. Braz J Med Biol Res. 2011 Apr;44(4):366-73. doi: 10.1590/s0100-879x2011007500020. Epub 2011 Feb 18. PMID: 21344132.

24. Nardi AE, Freire RC, Mochcovitch MD, Amrein R, Levitan MN, King AL, Valença AM, Veras AB, Paes F, Sardinha A, Nascimento I, de-Melo-Neto VL, Dias GP, E Silva AC, Soares-Filho GL, da Costa RT, Mezzasalma MA, de Carvalho MR, de Cerqueira AC, Hallak JE, Crippa JA, Versiani M. A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. 2012 Feb;32(1):120-6. doi: 10.1097/ JCP.0b013e31823fe4bd. Erratum in: J Clin Psychopharmacol. 2012 Apr;32(2):206. PMID: 22198456.

25. Freire RC, Amrein R, Mochcovitch MD, Dias GP, Machado S, Versiani M, Arias-Carrión O, Carta MG, Nardi AE. A 6-Year Posttreatment Follow-up of Panic Disorder Patients: Treatment With Clonazepam Predicts Lower Recurrence Than Treatment With Paroxetine. J Clin Psychopharmacol. 2017 Aug;37(4):429-434. doi: 10.1097/JCP.0000000000000740. PMID: 28609307.

26. Bighelli I, Trespidi C, Castellazzi M, Cipriani A, Furukawa TA, Girlanda F, Guaiana G, Koesters M, Barbui C. Antidepressants and benzodiazepines for panic disorder in adults. Cochrane Database Syst Rev. 2016 Sep 12;9(9):CD011567. doi: 10.1002/14651858.CD011567.pub2. PMID: 27618521; PMCID: PMC6457579.

27. Guina J, Rossetter SR, DeRHODES BJ, Nahhas RW, Welton RS. Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis. J Psychiatr Pract. 2015 Jul;21(4):281-303. doi: 10.1097/PRA.0000000000000091. PMID: 26164054.

28. Williams T, Hattingh CJ, Kariuki CM, Tromp SA, van Balkom AJ, Ipser JC, Stein DJ. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database Syst Rev. 2017 Oct 19;10(10):CD001206. doi: 10.1002/14651858.CD001206. pub3. PMID: 29048739; PMCID: PMC6360927.

29. Reich J, Yates W. A pilot study of treatment of social phobia with alprazolam. Am J Psychiatry. 1988 May;145(5):590-4. doi: 10.1176/ajp.145.5.590. PMID: 3282451.

30. Versiani M. A review of 19 double-blind placebo-controlled studies in social anxiety disorder (social phobia). World J Biol Psychiatry. 2000 Jan;1(1):27-33. doi: 10.3109/15622970009150563. PMID: 12607230.

31. Nagy LM, Krystal JH, Woods SW, Charney DS. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic followup study. Arch Gen Psychiatry. 1989 Nov;46(11):993-9. doi: 10.1001/archpsyc.1989.01810110035005. PMID: 2818144.

32. Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer-Brody S, Rosenbaum JF. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol. 1993 Aug;13(4):257-63. PMID: 8376613.

33. Worthington JJ 3rd, Pollack MH, Otto MW, McLean RY, Moroz G, Rosenbaum JF. Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder. Psychopharmacol Bull. 1998;34(2):199-205. PMID: 9641001.

34. Taylor D, Barnes T, Young AH. The Maudsley Prescribing Guidelines in Psychiatry 14^th ed. John Wiley & Sons. 2021.

35. Starcevic V. The reappraisal of benzodiazepines in the treatment of anxiety and related disorders. Expert Rev Neurother. 2014 Nov;14(11):1275-86. doi: 10.1586/14737175.2014.963057. Epub 2014 Sep 22. PMID: 25242262.

36. Starcevic V. The importance of distinguishing between dependence and addiction in the context of long-term benzodiazepine use. Aust N Z J Psychiatry. 2016 Nov;50(11):1111-1112. doi: 10.1177/0004867416644980. Epub 2016 Apr 18. PMID: 27091851.

37. Baldwin DS, Aitchison K, Bateson A, Curran HV, Davies S, Leonard B, Nutt DJ, Stephens DN, Wilson S. Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol. 2013 Nov;27(11):967-71. doi: 10.1177/0269881113503509. Epub 2013 Sep 24. PMID: 24067791.

38. Xing D, Ma XL, Ma JX, Wang J, Yang Y, Chen Y. Association between use of benzodiazepines and risk of fractures: a metaanalysis. Osteoporos Int. 2014 Jan;25(1):105-20. doi: 10.1007/ s00198-013-2446-y. Epub 2013 Sep 7. PMID: 24013517.

39. Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy. 2004 Sep;24(9):1177-85. doi: 10.1592/ phco.24.13.1177.38089. PMID: 15460178.

40. Williams T, McCaul M, Schwarzer G, Cipriani A, Stein DJ, Ipser J. Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis. Acta Neuropsychiatr. 2020 Aug;32(4):169-176. doi: 10.1017/ neu.2020.6. Epub 2020 Feb 10. PMID: 32039743.

41. Busto UE, Kaplan HL, Wright CE, Gomez-Mancilla B, Zawertailo L, Greenblatt DJ, Sellers EM. A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam. J Clin Psychopharmacol. 2000 Dec;20(6):628-35. doi: 10.1097/00004714-200012000-00008. PMID: 11106134.

42. Cordingley GJ, Dean BC, Hallett C. A multi-centre, double-blind parallel trial of bromazepam (‘Lexotan’) and lorazepam to compare the acute benefit-risk ratio in the treatment of patients with anxiety. Curr Med Res Opin. 1985;9(7):505-10. doi: 10.1185/03007998509109625. PMID: 2863089.

43. Stahl SM. Stahl’s Essential Psychopharmacology, Prescriber’s Guide 6th ed. Cambridge University Press, 2018.